Califf FDA Nomination Hearing Expected Before Holiday Season
This article was originally published in The Gray Sheet
Executive Summary
Senate HELP Committee has competing priorities, but FDA commissioner nominee still seems to have smooth path to confirmation.
You may also be interested in...
Consumer Groups Oppose Califf To Head FDA, Citing Industry Ties
Groups including Public Citizen say the Senate should reject the president's nomination of clinical trials expert and cardiologist Robert Califf as FDA commissioner due to his prior financial ties to industry. "The Gray Sheet" takes a look at his financial conflict of interest forms from former employer Duke University, which show relationships with a range of manufacturers – although more are from the pharmaceutical arena than the medical device space. But entries in Duke University’s conflict-of-interest disclosures don't always match up to those in the government's Open Payments database.
Califf Nomination May Show Confidence In His Bipartisan Appeal
After seven months as deputy commissioner for medical products and tobacco, Robert Califf tapped to be FDA Commissioner.
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.